182 related articles for article (PubMed ID: 37652661)
1. Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial.
Stamp L; Horne A; Mihov B; Drake J; Haslett J; Chapman PT; Frampton C; Dalbeth N
Ann Rheum Dis; 2023 Dec; 82(12):1626-1634. PubMed ID: 37652661
[TBL] [Abstract][Full Text] [Related]
2. Predicting Gout Flares in People Starting Allopurinol Using the Start-Low Go-Slow Dose Escalation Strategy.
Stamp LK; Horne A; Mihov B; Drake J; Haslett J; Chapman P; Frampton C; Dalbeth N
Arthritis Care Res (Hoboken); 2024 May; ():. PubMed ID: 38766703
[TBL] [Abstract][Full Text] [Related]
3. Allopurinol for chronic gout.
Seth R; Kydd AS; Buchbinder R; Bombardier C; Edwards CJ
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD006077. PubMed ID: 25314636
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Double-Blind, Active- and Placebo-Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout.
Poiley J; Steinberg AS; Choi YJ; Davis CS; Martin RL; McWherter CA; Boudes PF;
Arthritis Rheumatol; 2016 Aug; 68(8):2027-34. PubMed ID: 26989892
[TBL] [Abstract][Full Text] [Related]
5. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
[TBL] [Abstract][Full Text] [Related]
6. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.
Schumacher HR; Sundy JS; Terkeltaub R; Knapp HR; Mellis SJ; Stahl N; Yancopoulos GD; Soo Y; King-Davis S; Weinstein SP; Radin AR;
Arthritis Rheum; 2012 Mar; 64(3):876-84. PubMed ID: 22223180
[TBL] [Abstract][Full Text] [Related]
7. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
[TBL] [Abstract][Full Text] [Related]
8. Zhengqing fengtongning sustained-release tablets prevents gout flares in the process of ULT: A randomized, positive control, double-blind, double-simulation, multicenter trial.
Jia E; Hu S; Geng H; Zhu H; Xie J; Xiao Y; Jiang Y; Xiao M; Zhang J
Medicine (Baltimore); 2022 May; 101(18):e29199. PubMed ID: 35550468
[TBL] [Abstract][Full Text] [Related]
9. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.
Yamanaka H; Tamaki S; Ide Y; Kim H; Inoue K; Sugimoto M; Hidaka Y; Taniguchi A; Fujimori S; Yamamoto T
Ann Rheum Dis; 2018 Feb; 77(2):270-276. PubMed ID: 29102957
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With Gout.
Coleman GB; Dalbeth N; Frampton C; Haslett J; Drake J; Su I; Horne AM; Stamp LK
J Rheumatol; 2022 Dec; 49(12):1372-1378. PubMed ID: 35777814
[TBL] [Abstract][Full Text] [Related]
11. Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares.
Mandell BF; Fields TR; Edwards NL; Yeo AE; Lipsky PE
Clin Exp Rheumatol; 2021; 39(5):1085-1092. PubMed ID: 33427618
[TBL] [Abstract][Full Text] [Related]
12. An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
Becker MA; Fitz-Patrick D; Choi HK; Dalbeth N; Storgard C; Cravets M; Baumgartner S
Semin Arthritis Rheum; 2015 Oct; 45(2):174-83. PubMed ID: 26190562
[TBL] [Abstract][Full Text] [Related]
13. Does starting allopurinol prolong acute treated gout? A randomized clinical trial.
Hill EM; Sky K; Sit M; Collamer A; Higgs J
J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090
[TBL] [Abstract][Full Text] [Related]
14. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.
Stamp LK; Chapman PT; Barclay ML; Horne A; Frampton C; Tan P; Drake J; Dalbeth N
Ann Rheum Dis; 2017 Sep; 76(9):1522-1528. PubMed ID: 28314755
[TBL] [Abstract][Full Text] [Related]
15. Evaluating appropriate use of prophylactic colchicine for gout flare prevention.
George M; Pullman-Mooar S; Hussain F; Schumacher HR
Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1258-62. PubMed ID: 24376081
[TBL] [Abstract][Full Text] [Related]
16. Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial.
Taylor TH; Mecchella JN; Larson RJ; Kerin KD; Mackenzie TA
Am J Med; 2012 Nov; 125(11):1126-1134.e7. PubMed ID: 23098865
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Colchicine Prophylaxis for Gout Flares When Commencing Allopurinol.
Robinson PC; Dalbeth N; Donovan P
Arthritis Care Res (Hoboken); 2021 Oct; 73(10):1537-1543. PubMed ID: 32558298
[TBL] [Abstract][Full Text] [Related]
18. Febuxostat for treating chronic gout.
Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
[TBL] [Abstract][Full Text] [Related]
19. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.
Schlesinger N; Mysler E; Lin HY; De Meulemeester M; Rovensky J; Arulmani U; Balfour A; Krammer G; Sallstig P; So A
Ann Rheum Dis; 2011 Jul; 70(7):1264-71. PubMed ID: 21540198
[TBL] [Abstract][Full Text] [Related]
20. One- and 2-year flare rates after treat-to-target and tight-control therapy of gout: results from the NOR-Gout study.
Uhlig T; Karoliussen LF; Sexton J; Kvien TK; Haavardsholm EA; Perez-Ruiz F; Hammer HB
Arthritis Res Ther; 2022 Apr; 24(1):88. PubMed ID: 35443675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
